Patient derived xenografts generated from LKB1-deficient lung cancer patients displayed increased tumor necrosis with an impaired ability to adapt to metabolic stress mediated by the anti-angiogenic vascular endothelial growth factor (VEGF) inhibitor bevacizumab.206. The gene discussed is VEGFA; the disease is lung carcinoma.